Wooridul Huebrain Limited (118000.KS)
KRW 295.0
(-1.99%)
KRW 295.0
(-1.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -11.4 Billion KRW | -4642.28% |
| 2022 | -240.46 Million KRW | 86.53% |
| 2021 | -1.78 Billion KRW | -203.2% |
| 2020 | 1.72 Billion KRW | 162.98% |
| 2019 | 657.8 Million KRW | 109.92% |
| 2018 | -6.62 Billion KRW | -44.26% |
| 2017 | -4.59 Billion KRW | 20.07% |
| 2016 | -5.74 Billion KRW | 23.38% |
| 2015 | -7.5 Billion KRW | -23.65% |
| 2014 | -6.06 Billion KRW | -28.27% |
| 2013 | -4.72 Billion KRW | -41.12% |
| 2012 | -3.35 Billion KRW | 50.49% |
| 2011 | -6.76 Billion KRW | -133.59% |
| 2010 | -2.89 Billion KRW | -1028.79% |
| 2009 | 312.02 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 357.72 Million KRW | 103.75% |
| 2024 Q2 | 166.21 Million KRW | 93.53% |
| 2023 FY | -11.4 Billion KRW | -4642.28% |
| 2023 Q2 | -565.06 Million KRW | -176.03% |
| 2023 Q1 | 743.2 Million KRW | 304.53% |
| 2023 Q4 | -9.54 Billion KRW | -30294.45% |
| 2023 Q3 | 31.61 Million KRW | 105.59% |
| 2022 FY | -240.46 Million KRW | 86.53% |
| 2022 Q2 | 1.61 Billion KRW | 723.58% |
| 2022 Q1 | -259.12 Million KRW | -48.47% |
| 2022 Q3 | -38.88 Million KRW | -102.41% |
| 2022 Q4 | 183.71 Million KRW | 572.45% |
| 2021 Q3 | -208.09 Million KRW | 34.97% |
| 2021 Q1 | -1.08 Billion KRW | -48.06% |
| 2021 FY | -1.78 Billion KRW | -203.2% |
| 2021 Q2 | -319.97 Million KRW | 70.45% |
| 2021 Q4 | -174.52 Million KRW | 16.13% |
| 2020 Q4 | -731.28 Million KRW | -60.6% |
| 2020 Q2 | -694.63 Million KRW | -24.14% |
| 2020 Q1 | -559.54 Million KRW | -132.22% |
| 2020 FY | 1.72 Billion KRW | 162.98% |
| 2020 Q3 | -455.34 Million KRW | 34.45% |
| 2019 Q1 | -869.37 Million KRW | 67.04% |
| 2019 FY | 657.8 Million KRW | 109.92% |
| 2019 Q3 | -245.89 Million KRW | 65.03% |
| 2019 Q4 | 1.73 Billion KRW | 806.15% |
| 2019 Q2 | -703.12 Million KRW | 19.12% |
| 2018 Q1 | -1.81 Billion KRW | -510.95% |
| 2018 Q4 | -2.63 Billion KRW | -90.07% |
| 2018 Q3 | -1.38 Billion KRW | -76.92% |
| 2018 FY | -6.62 Billion KRW | -44.26% |
| 2018 Q2 | -784.3 Million KRW | 56.88% |
| 2017 FY | -4.59 Billion KRW | 20.07% |
| 2017 Q2 | -1.65 Billion KRW | -32.39% |
| 2017 Q3 | -2.12 Billion KRW | -28.12% |
| 2017 Q4 | 442.58 Million KRW | 120.82% |
| 2017 Q1 | -1.25 Billion KRW | 37.5% |
| 2016 Q1 | -1.41 Billion KRW | 8.54% |
| 2016 FY | -5.74 Billion KRW | 23.38% |
| 2016 Q4 | -2 Billion KRW | -81.82% |
| 2016 Q3 | -1.1 Billion KRW | 10.07% |
| 2016 Q2 | -1.22 Billion KRW | 13.33% |
| 2015 Q4 | -1.54 Billion KRW | 29.54% |
| 2015 Q3 | -2.19 Billion KRW | -3.94% |
| 2015 FY | -7.5 Billion KRW | -23.65% |
| 2015 Q1 | -1.64 Billion KRW | 37.9% |
| 2015 Q2 | -2.11 Billion KRW | -28.14% |
| 2014 Q1 | -1.17 Billion KRW | 46.52% |
| 2014 FY | -6.06 Billion KRW | -28.27% |
| 2014 Q4 | -2.65 Billion KRW | -157.05% |
| 2014 Q3 | -1.03 Billion KRW | 14.3% |
| 2014 Q2 | -1.2 Billion KRW | -2.48% |
| 2013 Q1 | -727.07 Million KRW | -3.06% |
| 2013 Q3 | -1.05 Billion KRW | -41.87% |
| 2013 FY | -4.72 Billion KRW | -41.12% |
| 2013 Q2 | -745.98 Million KRW | -2.6% |
| 2013 Q4 | -2.19 Billion KRW | -107.72% |
| 2012 FY | -3.35 Billion KRW | 50.49% |
| 2012 Q2 | -1.78 Billion KRW | -493.38% |
| 2012 Q1 | -300.62 Million KRW | 91.99% |
| 2012 Q4 | -705.51 Million KRW | -25.66% |
| 2012 Q3 | -561.46 Million KRW | 68.53% |
| 2011 Q2 | -2.74 Billion KRW | -4023.47% |
| 2011 Q4 | -3.75 Billion KRW | -977.95% |
| 2011 FY | -6.76 Billion KRW | -133.59% |
| 2011 Q1 | 69.84 Million KRW | 105.86% |
| 2011 Q3 | -347.96 Million KRW | 87.3% |
| 2010 Q3 | -1 Billion KRW | -18.36% |
| 2010 Q2 | -850.9 Million KRW | -660.65% |
| 2010 Q1 | 151.77 Million KRW | 0.0% |
| 2010 FY | -2.89 Billion KRW | -1028.79% |
| 2010 Q4 | -1.19 Billion KRW | -18.33% |
| 2009 FY | 312.02 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Daewoong Co., Ltd. | 195.87 Billion KRW | 105.822% |
| PharmGen Science, Inc. | 9.12 Billion KRW | 224.947% |